Major depression

15 trials 5 recruiting MedDRA PT
15 Registered trials
5 Recruiting
15 Unique sponsors
14 Unique IMPs
10 Commercial trials
Drug classes (ATC)
— ATC code not specified 10
N Neurology/Psychiatry (ATC N) 4
J Anti-infectives (ATC J) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 13 substances
Tetracycline 1 substance
Phase III: 4 Phase II: 8 Phase IV: 1 Phase I (Other): 1 Other: 1

Filter these 15 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 15 trials

Phase III

4 trials
  • Dr. Willmar Schwabe GmbH & Co. KG Commercial
    LAVENDER OIL
    2025-521744-37-00 2 countries 2025 n=500
    Recruiting
  • Janssen - Cilag International Commercial
    SELTOREXANT
    2023-509070-36-00 9 countries 2025 n=202
    Recruiting
  • Mggm LLC Commercial
    DEXTROMETHADONE HYDROCHLORIDE
    2023-507399-27-00 1 country 2024 n=130
    Ended
  • Region Skane Academic
    IMP not specified
    2022-502270-17-00 1 country 2023 n=80
    Ended

Phase II

8 trials
  • Beckley Psytech Limited Commercial
    IMP not specified
    2024-513457-70-00 3 countries 2023 n=87
    Ended
  • Draig Therapeutics Limited Commercial
    DT-101
    2025-522784-15-00 3 countries 2026 n=113
    Recruiting
  • GH Research Ireland Limited Commercial
    MEBUFOTENIN
    2023-510047-37-00 5 countries 2023 n=81
    Ended
  • HMNC Holding GmbH Commercial
    NELIVAPTAN
    2024-513104-34-00 7 countries 2024 n=274
    Ended
  • Fraunhofer Institute For Translational Medicine And Pharmacology ITMP Academic
    DEXAMFETAMINE SULFATE
    2024-515395-12-00 1 country 2025 n=105
    Recruiting
  • Narodni Ustav Dusevniho Zdravi Academic
    KETAMINE HYDROCHLORIDE; MIDAZOLAM; PSILOCYBINE
    2024-515899-13-00 1 country 2024 n=60
    Ended
  • Ostfold Hospital Trust Academic
    IMP not specified
    2025-521330-29-00 1 country n=230
    Pending
  • Provincia Lombardo Veneta Dell’Ordine Ospedaliero Di San Giovanni Di Dio Fatebenefratelli Academic
    MINOCYCLINE HYDROCHLORIDE
    2024-520076-10-01 1 country n=100
    Pending

Phase IV

1 trial
  • Fidia Farmaceutici S.p.A. Commercial
    CITALOPRAM HYDROBROMIDE; HYPOTHALAMIC PHOSPHOLIPIDS
    2024-512293-10-00 1 country 2018 n=150
    Recruiting

Phase I (Other)

1 trial
  • Ketabon GmbH Commercial
    ESKETAMINE HYDROCHLORIDE; KETAMINE HYDROCHLORIDE
    2023-503971-45-00 1 country 2023 n=26
    Ended

Other

1 trial
  • Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesc O A.C.R.A.F. S.p.A. Commercial
    IMP not specified
    2024-511612-24-00 1 country 2024 n=64
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesc O A.C.R.A.F. S.p.A. Commercial 1 Other 0
Ketabon GmbH Commercial 1 Phase I (Other) 0
Beckley Psytech Limited Commercial 1 Phase II 0
Draig Therapeutics Limited Commercial 1 Phase II 1
GH Research Ireland Limited Commercial 1 Phase II 0
HMNC Holding GmbH Commercial 1 Phase II 0
Dr. Willmar Schwabe GmbH & Co. KG Commercial 1 Phase III 1
Janssen - Cilag International Commercial 1 Phase III 1
Mggm LLC Commercial 1 Phase III 0
Fidia Farmaceutici S.p.A. Commercial 1 Phase IV 1
Fraunhofer Institute For Translational Medicine And Pharmacology ITMP Academic 1 Phase II 1
Narodni Ustav Dusevniho Zdravi Academic 1 Phase II 0
Ostfold Hospital Trust Academic 1 Phase II 0
Provincia Lombardo Veneta Dell’Ordine Ospedaliero Di San Giovanni Di Dio Fatebenefratelli Academic 1 Phase II 0
Region Skane Academic 1 Phase III 0
New trials by year
2023
4
2024
4
2025
3
2026
1
← All indication landscapes